M6P Therapeutics

M6P Therapeutics is a private, preclinical-stage biotech targeting rare Lysosomal Storage Disorders (LSDs) with a novel platform based on mannose 6-phosphate (M6P) biology. The company's S1S3 co-expression platform aims to produce enzyme replacement and gene therapy products with superior lysosomal targeting, potentially improving efficacy over existing treatments. Operating in a high-need, orphan drug space, M6PT is advancing its pipeline with the goal of delivering more effective therapies for patients with limited or no treatment options.

S1S3 co-expression platform technology designed to enhance mannose 6-phosphate (M6P) content on lysosomal enzymes to improve cellular uptake and lysosomal targeting for both enzyme replacement and gene therapies.

M6PT competes in the LSD space against established ERT products from companies like Sanofi and Takeda, as well as numerous biotechs developing next-gen ERTs, substrate reduction therapies, gene therapies (e.g., Avrobio, Sangamo), and gene editing approaches. Differentiation hinges on demonstrating superior tissue targeting via its high-M6P platform.